Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes
J. Clin. Invest. Jehonathan H. Pinthus, et al. 114:1774 doi:10.1172/JCI22284 [
Go to this article.]
Figure 5The effect of systemic treatment with erbB2-specific T bodies on WISH-PC14 BM lesions is dependent on the preirradiation of mice. (
A and
B) SCID mice bearing an established intraosseous WISH-PC14 xenograft either were not preconditioned (
A) or were preconditioned with 2 Gy TBI (
B) 24 hours before i.v. administration of erbB2- or TNP-specific CR–bearing lymphocytes or medium (
n = 10 mice per group). PSA levels in the mouse sera were determined. Squares, circles, and triangles represent medium, TNP-, and erbB2-specific CR–bearing lymphocytes, respectively, injected into recipient SCID mice.
